Skip to main content
Older women talking around a table

Is there OS data for KISQALI across different age groups, including elderly patients?

There is overall survival data for KISQALI® (ribociclib), in combination with an aromatase inhibitor (AI) or fulvestrant, across all age groups in the MONALEESA trials, including in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC). Results are from an exploratory, pooled, post hoc analysis of data from the 3 phase III MONALEESA trials. Review the efficacy and safety for data across age groups below.1 
References: 1. Hart LL, Im S-A, Tolaney SM, et al. Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials. Eur J Cancer. 2025;217(115225). doi:10.1016/j.ejca.2025.115225 2. Hart LL, Im S-A, Tolaney SM, et al. Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials. Eur J Cancer. 2025;217(115225);(suppl). doi:10.1016/j.ejca.2025.115225 3. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp. 4. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738-1748. doi:10.1056/NEJMoa1609709 5. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465-2472. doi:10.1200/JCO.2018.78.9909 6. Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915. doi:10.1016/S1470-2045(18)30292-4